4.15
+2.22%
Close of 9 Nov 2026, in CHF
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Idorsia
Its shares trade on SIX under the ticker IDIA.SW. It has been listed since 16 June 2017. In the fiscal year to 31 December 2025, it reported revenue of CHF 221.0m and a net loss of CHF 112.0m. At that date it held total assets of CHF 465.9m and shareholders' equity of −CHF 1.14bn.
Idorsia Ltd. operates as a biopharmaceutical firm which focuses on discovery, development and commercialization of innovative medicines for unmet medical needs. The company is headquartered in Allschwil, Basel-Landschaft. The company went IPO on 2017-06-16. The firm will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders and orphan diseases. The firm's development compounds target a number of different diseases such as: Resistant Hypertension, Systemic lupus erythematosus, Chronic insomnia and Fabry disease, among others.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 16 Jun 2017
- Employees
- 636
- Website
- idorsia.com ↗
Leadership
Pay as last reported
- Dr. Jean-Paul ClozelChairman of the Board, since 2017CHF 234,183
- Dr. Srishti GuptaChief Executive Officer, Executive Director, Member of the Executive Board, since 2021CHF 158,842
- Dr. Mathieu SimonVice Chairman of the Board, Lead Independent DirectorCHF 219,434
- Mr. Arno GroenewoudChief Financial Officer, Executive Vice President, Member of the Executive Board
- Ms. Martine ClozelExecutive Vice President, Chief Scientific Officer, Member of the Executive Board
- Mr. Julien GanderExecutive Vice President, Group General Counsel, Member of the Executive Board
- Mr. Alberto GimonaExecutive Vice President, Head of Global Clinical Development, Member of the Executive Board
- Mr. Bart FiliusNon-Executive DirectorCHF 102,684
- Dr. Sophie KornowskiNon-Executive Independent DirectorCHF 141,752
- Mr. Sandy MahatmeNon-Executive Independent DirectorCHF 149,511
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 88
- Environment
- 99
- Social
- 99
- Governance
- 65
- Direct emissions (scope 1)
- 475 t
- Energy emissions (scope 2)
- 507.8 t
- Women in the workforce
- 46%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Idorsia Ltd benefits from several strengths which contribute to its success in the market. These include:
Weaknesses
- Despite its strengths, Idorsia Ltd also faces certain weaknesses that can hinder its growth and performance. These weaknesses include:
Opportunities
- Idorsia Ltd has various opportunities to capitalize on and expand its market presence. These include:
Threats
- While pursuing its goals, Idorsia Ltd must also be aware of potential threats that could negatively impact its performance. These threats include:
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.